Why the PYC Therapeutics (ASX:PYC) share price is up 11% today

The PYC Therapeutics share price is higher today after the company announced that it has added another drug to its pipeline.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Today, the PYC Therapeutics (ASX: PYC) share price is up 11.11% to 20 cents at the time of writing. The surge in the PYC Therapeutics share price came after the company added a new drug to its pipeline.

row of piggy banks with large one receiving injection representing rising Immutep share price

Image source: Getty Images

What was the announcement?

PYC Therapeutics has added a new drug to its pipeline for the treatment of 'Autosomal Dominant Optic Atrophy' (ADOA) caused by mutations in the OPA1 gene. The disease causes blindness and, according to PYC Therapeutics, it affects 1 in every 30,000 people. The company has also advised that no treatment is currently available for this type of ADOA, with those suffering from the disease losing vision rapidly in childhood and early adolescence. 

The new drug, known as VP-002, works by correcting a protein deficiency in cells which are affected by the OPA1 type of ADOA. The company expects the drug to have a rapid path into clinical development due to synergies across its existing drug programs. The drug will utilise the same proprietary delivery method as other drugs in PYC Therapeutics' pipeline. The company has stated that it is in the pre-clinical stages of developing a technology for the delivery of drugs directly into the retina for blinding eye diseases. According to PYC Therapeutics, it will also use its existing 'backbone' chemistry to develop VP-002.

About the PYC Therapeutics share price

PYC Therapeutics is a pharmaceutical company which is developing a range of drugs that can be injected directly into cells. The drug maker has been listed on the ASX since 2005.

On 6 October 2020, PYC Therapeutics made an announcement that it had added another drug to its pipeline. The new drug is intended to treat diabetes-related retinopathy and age-related macular degeneration which, according to the company, are the two leading causes of blindness globally.

In the year to 30 June 2020, PYC Therapeutics posted a loss of 0.26 cents per share. The company had $7.24 million cash on hand at 30 June 2020.

The PYC Therapeutics share price is up 365.12% since its 52-week low of 4.3 cents and is up 233.33% since the beginning of the year. The PYC Therapeutics share price is up 233.33% since this time last year.

Motley Fool contributor Chris Chitty has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

a couple consider the advice from a man with documents laid out on a table and the man holding a tablet in his hand.
Financial Shares

3 ASX 200 financial shares to sell: experts

ASX 200 financial shares are down 2.5% over six months and up 2.1% in 2026-to-date.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Broker Notes

What is Morgans saying about Cochlear and Northern Star shares?

Here's what the broker is saying about these big names following their updates.

Read more »

A woman with a mobile phone in her hand looks sceptical with a puzzled expression on her face with an eyebrow raised and pursed lips.
Broker Notes

Buy, hold, sell: NextDC, Hub24, PLS Group shares

The market is pessimistic about the next round of talks between the US and Iran.

Read more »

A team of people giving the thumbs up sign.
Broker Notes

5 ASX 200 shares with renewed buy ratings this week

Brokers have indicated continuing confidence in Cochlear, REA, and several other ASX 200 shares.

Read more »

a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.
Share Gainers

Why Deep Yellow, Develop Global, Resolute Mining, and Santos shares are pushing higher today

These shares are catching the eye on Thursday. But why?

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Black Cat, Mirvac, Qantas, and Temple & Webster shares are falling today

These shares are having a tough session. But why?

Read more »

An old-fashioned news boy stands on a stool and yells through a microphone in an open field.
Share Market News

Why is everyone talking about Core Lithium, Ampol and Santos shares on Thursday?

Ampol, Core Lithium and Santos shares are making waves on Thursday. But why?

Read more »